Federal Research Funding Cuts Already Disrupting Clinical Trials Despite Congressional Reprieve

In the long arc of scientific progress, the health of a civilization can often be measured by how it tends to the seeds of future knowledge. In early 2026, the United States Congress pulled back from proposed cuts that would have gutted federal research funding, yet the damage had already taken root: hundreds of clinical trials were halted, tens of thousands of patients lost access to experimental therapies, and a generation of early-career scientists—disproportionately women—found their life's work suspended mid-sentence. The legislative reprieve arrived, but for many, it arrived too late.